VERA — Vera Therapeutics, Inc. stock price, charts and financials

QT64Vera Therapeutics, Inc.

Vera Therapeutics, Inc. (NASDAQ: VERA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
31.85
-1.04-3.15%
OverviewShort InterestFilings
VERAQT64Vera Therapeutics, Inc.·NASDAQ
31.85-3.15%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
BCRX+2.38%$9.60IMNM+3.20%$25.83MLYS-0.29%$27.27VCEL-1.03%$44.63KLRA-0.64%$18.54SION-92.03%$4.07ADMA-0.56%$9.85NUVB-1.21%$6.51
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand71.78MPerf Week2.46%
Market Cap2.36BForward P/E-EPS next Y-3.91Insider Trans-0.39%Shs Float58.51MPerf Month-22.52%
Enterprise Value2.32BPEG0.12EPS next Q-Inst Own-Short Float25.78%Perf Quarter-8.33%
Income-370.43MP/S0.00EPS this Y-Inst Trans-Short Ratio9.54Perf Half Y-19.68%
Sales0.00P/B4.70EPS next Y36.77%ROA-59.34%Short Interest15.08MPerf YTD-35.05%
Book/sh-P/C-EPS next 5Y-ROE-74.86%52W High54.28 -41.32%Perf Year70.86%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-66.50%52W Low18.47 72.47%Perf 3Y78.65%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.91% 5.21%Perf 5Y82.72%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-101.45%Oper. Margin0.00%ATR (14)2.00Perf 10Y-
Dividend Ex-Date-Quick Ratio13.64Sales Y/Y TTM-Profit Margin0.00%RSI (14)40.89Recom2.00
Dividend Gr. 3/5Y-Current Ratio13.64EPS Q/Q-108.64%SMA20-7.40%Beta0.88Target Price87.14
Payout0.00%Debt/Eq0.15Sales Q/Q-SMA50-9.84%Rel Volume0.77Prev Close32.89
Employees249LT Debt/Eq0.13EarningsNov 11SMA200-15.57%Avg Volume1.82MPrice31.85
IPO DateMay 14, 2021Option/ShortYes / YesEPS/Sales Surpr.-27.22% -Net Debt/EBITDA0.11Volume1,393,434Change-3.15%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-08-26ReiteratedNeedham$125
Jul-08-26ReiteratedHC Wainwright & Co.Buy$90 → $125
Jul-08-26ReiteratedWedbushNeutral$33 → $43
Jul-08-26ReiteratedGuggenheimBuy$76
Jun-02-26ReiteratedJefferiesBuy$6.00 → $60
Jun-02-26ReiteratedGoldman SachsBuy$95 → $90
May-15-26ReiteratedEvercore ISI GroupOutperform$97 → $91
Mar-11-26UpgradeWolfe ResearchPeer Perform → Outperform
Dec-19-25ReiteratedGoldman SachsBuy$95
Dec-11-25ReiteratedWedbushNeutral$34 → $33
Latest News
Aug-07-26
Aug-07-2604:05PM
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jul-11-26
Jul-11-2602:02PM
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launchmarketbeat.com
Jul-10-26
Jul-10-2604:05PM
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
11:14AM
Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% RunYahoo
Jul-09-26
Jul-09-2608:00AM
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turnerglobenewswire.com
Jul-07-26
Jul-07-2607:12PM
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy TranscriptSeekingAlpha
12:42PM
US FDA approves Vera's kidney disease drugreuters.com
12:37PM
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathyglobenewswire.com
Jul-06-26
Jul-06-2611:39AM
What's Going on with Vera Therapeutics Stock on Monday?benzinga.com
Jun-23-26
Jun-23-2602:50PM
Healthcare's Quiet Comeback: Innovation, Obesity Drugs And New OpportunitiesSeekingAlpha
Company

Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A
000————
Gross Profit
000————
Selling, General and Administrative Excl. Other1004124————
Research and Development21512678————
Other Operating Expense
000————
Operating Income-315-167-102————
Interest Expense884————
Unusual Expense
———————
Non-Operating Income (Expense)232310————
Net Income Before Taxes-300-152-96————
Income Taxes
000————
Consolidated Net Income-300-152-96————
Net Income From Continuing Operations-300-152-96————
Net Income-300-152-96————
EPS (Recurring)-4.66-2.75-2.25————
EPS (Basic, Before Extraordinaries)-4.66-2.75-2.25————
EPS (Diluted)-4.66-2.75-2.25————
EBITDA-292-144-92————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding645543————
Market Capitalization3,2412,326661————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$61.18$49.24$37.31$25.38$13.44● Close Price0.00M0.49M0.98M1.47M1.96MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fordyce MarshallPRESIDENT AND CEOJul 07 '26Sale42.3046,2501,956,187151,994Jul 09
Fordyce MarshallPRESIDENT AND CEOJun 23 '26Sale37.9318,500701,769198,244Jun 24
Fordyce MarshallPRESIDENT AND CEOMay 12 '26Sale36.7418,500679,747216,744May 13
Fordyce MarshallPRESIDENT AND CEOApr 14 '26Sale44.0522,9511,011,051235,244Apr 15
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRMar 13 '26Option Exercise3.9410,00039,39675,754Mar 16
Brenner RobertChief Medical OfficerFeb 23 '26Sale41.982,15190,30750,947Feb 25
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCRFeb 23 '26Sale41.983,117130,86464,722Feb 25
Grant SeanCHIEF FINANCIAL OFFICERFeb 23 '26Sale41.984,949207,778114,181Feb 25
Fordyce MarshallPRESIDENT AND CEOFeb 23 '26Sale41.9816,925710,578257,163Feb 25
JOHNSON DAVID LEEChief Operating OfficerFeb 23 '26Sale41.982,579108,27645,727Feb 25
Turner William D.Chief Regulatory OfficerFeb 23 '26Sale41.982,18791,81945,313Feb 25
Skelton Laurence MatthewChief Commercial OfficerFeb 23 '26Sale41.981,58266,41964,218Feb 25
Turner William D.Chief Regulatory OfficerDec 15 '25Option Exercise15.5310,000155,30032,500Dec 17
Turner William D.Chief Regulatory OfficerDec 15 '25Sale50.0810,000500,76722,500Dec 17
ENRIGHT PATRICK GDirectorDec 11 '25Buy42.505,882249,9855,882Dec 15
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.